RFP
LGND icon

Root Financial Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Root Financial Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19
Closed -$3.79K – 1955
2026
Q1 		$3.79K Buy
19
+12
+171% +$2.37K ﹤0.01% 2054
2025
Q4 		$1.32K Buy
+7
New +$1.34K ﹤0.01% 2056

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Root Financial Partners's LGND Position: Q2 2026 in Review

Root Financial Partners sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 19 shares — an estimated $3.79K sold.

Root Financial Partners first reported a position in LGND in Q4 2025 and held it in 2 quarters. The position peaked at $3.79K in Q1 2026. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Root Financial Partners reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Root Financial Partners sold 19 Ligand Pharmaceuticals shares in Q2 2026, an estimated $3.79K.
  • Root Financial Partners first reported a position in Ligand Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Root Financial Partners's Ligand Pharmaceuticals position peaked at $3.79K in Q1 2026.
  • 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.